Search Result

Results for "

angiotensin receptor blockers

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Angiotensin Receptor (20) Angiotensin-converting Enzyme (ACE) (2) Acyltransferase (1) Apoptosis (1) Arrestin (3) Bacterial (1) Drug Derivative (2) Drug Metabolite (2) Isotope-Labeled Compounds (4) Mas-related G-protein-coupled Receptor (MRGPR) (1) Natriuretic Peptide Receptor (NPR) (1) Orphan GPCR (1) P2Y Receptor (4) PPAR (2) Reference Standards (3) Renin (1) SARS-CoV (6)
By Research Areas:	Cancer (6) Cardiovascular Disease (24) Endocrinology (3) Infection (6) Inflammation/Immunology (4) Metabolic Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Angiotensin Receptor Angiotensin-converting Enzyme (ACE)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-119706

Barbadin Maximum Cited Publications 16 Publications Verification	Apoptosis Arrestin	Others
Barbadin is a novel and selective β-arrestin/β2-adaptin interaction inhibitor, has IC₅₀ values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-vasopressin and angiotensin-II type-1 receptors. Barbadin can induce apoptosis .

HY-B0205

Candesartan 5+ Cited Publications CV 11974	Angiotensin Receptor PPAR	Cardiovascular Disease Endocrinology Cancer
Candesartan (CV 11974) is an orally active **angiotensin II AT1-Receptor** blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

HY-P1656

(D-Pro7)-Angiotensin I/II (1-7) 1 Publications Verification	Angiotensin Receptor Mas-related G-protein-coupled Receptor (MRGPR)	Cardiovascular Disease
(D-Pro7)-Angiotensin I/II (1-7) is a potent Mas receptor inhibitor with a K_i of 0.001 μM for rat receptors. (D-Pro7)-Angiotensin I/II (1-7) competitively blocks the binding of Angiotensin-(1-7) to the Mas receptor and attenuates the vasodilatory effect of rat aortas under physiological and hypertensive conditions. (D-Pro7)-Angiotensin I/II (1-7) can be used for studies on the function of the renin-angiotensin system and the pathological mechanisms of hypertension .

HY-160187

AAA	Orphan GPCR Angiotensin Receptor	Cardiovascular Disease
AAA is an orally active 20-HETE receptor antagonist. AAA exerts antihypertensive and organoprotective effects. AAA blocks 20-HETE prohypertensive actions, suppresses intrarenal and circulating angiotensin II levels, and interferes with renin-angiotensin system interactions. AAA attenuates development of, and reverses established, ANG II (HY-13948)-dependent malignant hypertension. AAA reduces albuminuria, glomerulosclerosis, and cardiac hypertrophy linked to malignant hypertension. AAA can be used for the research of malignant hypertension .

HY-12765

Losartan Carboxylic Acid E-3174; EXP-3174	Drug Metabolite Angiotensin Receptor	Cardiovascular Disease
Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensin II receptor type 1 (AT1) antagonist. The K_i values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensin II-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure .

HY-P2141

TRV-120027 3 Publications Verification TRV027	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027, a β-arrestin-1-biased agonist of *the angiotensin* II receptor type 1 (AT1R)*, engages β-arrestins while blocking* G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R-β-arrestin-1-TRPC3-PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .

HY-P990951

Vixticibart REGN-5381	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease
Vixticibart (REGN-5381) is a fully human IgG4 monoclonal antibody and NPR1 agonist that targets NPR1. Vixticibart stabilizes the receptor in an activated conformation by binding to the N-terminal domain of NPR1, and enhances the activity of endogenous ligands ANP and BNP without blocking ligand binding when these ligands are present. Vixticibart exerts vasodilatory and hypotensive effects by inducing cGMP production, preferentially dilating venous vessels to reduce systolic and venous pressure, but does not induce diuresis and may trigger a compensatory increase in heart rate. Vixticibart produces a synergistic hypotensive effect when combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and is currently mainly used in research related to heart failure and hypertension .

HY-107867

(±)-Clopidogrel bisulfate	P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
(±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-12765S

Losartan-d4 (carboxylic acid) E-3174 d₄; EXP-3174 d₄	Angiotensin Receptor	Cardiovascular Disease Endocrinology Cancer
Losartan-d₄ carboxylic acid (E-3174-d₄) is the deuterium labeled Losartan Carboxylic Acid (HY-12765). Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensin II receptor type 1 (AT1) antagonist. The K_i values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensin II-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure.

HY-W414915

Valsartan methyl ester CGP 48933 methyl ester	Drug Derivative Angiotensin Receptor	Cardiovascular Disease Cancer
Valsartan (CGP 48933) methyl ester is the methyl ester derivative of Valsartan (HY-18204). Valsartan is a selective and orally active angiotensin II type 1 (AT1) receptor blocker (ARB) with potent antihypertensive and cardioprotective effects. Valsartan competitively binds to AT1 receptors, inhibiting the binding of angiotensin II to AT1 receptors, thereby blocking angiotensin II-mediated vasoconstriction, sodium retention, and myocardial hypertrophy signaling pathways. Valsartan reduces systolic blood pressure in L-NAME-induced hypertensive rats. Valsartan can be used for the study and treatment of arterial hypertension, hypertensive heart disease, and heart failure .

HY-138067

SSAA09E2	SARS-CoV	Inflammation/Immunology
SSAA09E2 is an inhibitor of SARS-CoV (Severe acute respiratory syndrome-Coronavirus) replication, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV, Angiotensin Converting Enzyme-2 (ACE2) .

HY-P10933

PRO20	Renin	Cardiovascular Disease
PRO20 is a specific and competitive (pro)renin receptor (PRR) antagonist. PRO20 inhibits Prorenin-induced calcium influx with an IC₅₀ value of 81 nmol/L. PRO20 exerts antihypertensive activity by blocking the binding of prorenin to the PRR, inhibiting the activation of the renin-angiotensin system (RAS), and reducing the production of angiotensin II (Ang II). PRO20 is promising for research of antihypertensive agents .

HY-P5407

HD5	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection Cancer
HD5 is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer .

HY-P2141A

TRV-120027 TFA 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027 TFA, a β-arrestin-1-biased agonist of *the angiotensin* II receptor type 1 (AT1R)*, engages ?-arrestins while blocking* G-protein signaling . TRV120027?TFA induces?acute?catecholamine?secretion?through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the?acute decompensated heart failure (ADHF) treatment .

HY-10382

EXP-6803	Angiotensin Receptor	Cardiovascular Disease
EXP-6803 is a specific nonpeptide angiotensin II receptor antagonist with antihypertensive activity. EXP-6803 inhibits the contractile response to angiotensin II with a pA₂ value of 7.20. EXP-6803 effectively blocks responses to angiotensin I and II while not affecting responses to bradykinin or acetylcholine in guinea pig ileum. EXP-6803 can be used for hypertension research .

HY-B0205R

Candesartan (Standard) CV 11974 (Standard)	Reference Standards Angiotensin Receptor PPAR	Cardiovascular Disease Endocrinology Cancer
Candesartan (Standard) is the analytical standard of Candesartan. This product is intended for research and analytical applications. Candesartan (CV 11974) is an orally active **angiotensin II AT1-Receptor** blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

HY-B0205S

Candesartan-d4 CV-11974-d₄	Angiotensin Receptor	Others
Candesartan-d₄ (CV-11974-d₄) is the deuterium labeled Candesartan (HY-B0205). Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI).

HY-N9530

1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone	Acyltransferase Angiotensin Receptor Bacterial	Infection Cardiovascular Disease Metabolic Disease
1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone, a quinolone alkaloid, is a diacylglycerol acyltransferase inhibitor and **angiotensin II receptor** blocker, with IC₅₀s of 20.1 μM and 34.1 μM, respectively. 1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone shows potent anti-Helicobacter pylori activity with the MIC of 10 μg/mL .

HY-160292

Enoltasosartan	Angiotensin Receptor	Cardiovascular Disease
Enoltasosartan is an **angiotensin II (AngII) receptor** blocker .

HY-19022

BW A256C	Angiotensin Receptor	Cardiovascular Disease Others Metabolic Disease
Palatrigine is a compound with angiotensin-converting enzyme inhibitory and beta-adrenergic receptor blocking properties .

HY-19207

GA-0056	Angiotensin Receptor	Cardiovascular Disease
GA-0056 is an **angiotensin II receptor** blocker. GA-0056 can be used in the research of heart disease .

HY-106123

Pomisartan	Angiotensin Receptor	Cardiovascular Disease
Pomisartan is an orally active angiotensin II receptor type AT1 antagonist (IC₅₀=0.26 μM). Pomisartan works by inhibiting the binding of angiotensin II to the AT1 receptor, thereby blocking the vasoconstriction and aldosterone release caused by this interaction. Pomisartan results in a blood pressure-lowering effect .

HY-W414915R

Valsartan methyl ester (Standard) CGP 48933 methyl ester (Standard)	Reference Standards Drug Derivative Angiotensin Receptor	Cardiovascular Disease
Valsartan (CGP 48933) methyl ester (Standard) is the analytical standard of Valsartan methyl ester (HY-W414915). This product is intended for research and analytical applications. Valsartan methyl ester is the methyl ester derivative of Valsartan (HY-18204). Valsartan is a selective angiotensin II type 1 (AT1) receptor blocker (ARB) with potent antihypertensive and cardioprotective effects. Valsartan competitively binds to AT1 receptors, inhibiting the binding of angiotensin II to AT1 receptors, thereby blocking angiotensin II-mediated vasoconstriction, sodium retention, and myocardial hypertrophy signaling pathways. Valsartan reduces systolic blood pressure in L-NAME-induced hypertensive rats. Valsartan can be used for the study and treatment of arterial hypertension, hypertensive heart disease, and heart failure .

HY-12765S1

Losartan carboxylic acid-d4 hydrochloride	Isotope-Labeled Compounds Angiotensin Receptor	Cardiovascular Disease
Losartan carboxylic acid-d₄ (hydrochloride) is deuterium labeled Losartan Carboxylic Acid. Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensin II receptor type 1 (AT1) antagonist. The K_i values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensin II-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure .

HY-12765R

Losartan Carboxylic Acid (Standard) E-3174 (Standard); EXP-3174 (Standard)	Drug Metabolite Reference Standards Angiotensin Receptor	Cardiovascular Disease
Losartan Carboxylic Acid (Standard) is the analytical standard of Losartan Carboxylic Acid. This product is intended for research and analytical applications. Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensin II receptor type 1 (AT1) antagonist. The Ki values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensin II-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure [4].

HY-107867S1

(Rac)-Clopidogrel hydrogen-d9 sulfate	Isotope-Labeled Compounds P2Y Receptor	Inflammation/Immunology
(Rac)-Clopidogrel hydrogen-d₉ sulfate is the deuterium labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-122282

AZ11657312	Angiotensin Receptor	Cardiovascular Disease
AZ11657312 is a P2X7 receptor antagonist with activity to restore stress natriuresis. AZ11657312 significantly increased renal medullary perfusion, only in mice treated with angiotensin II. AZ11657312 improves tissue oxygenation by blocking P2X7R, especially in areas of the kidney that are underoxygenated. Administration of AZ11657312 increased sodium excretion up to sixfold while normalizing blood pressure .

HY-107867S2

Clopidogrel-13C,d3 sulfate	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease
Clopidogrel- ¹³C,d₃ sulfate is the deuterium and ¹³C-labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-170767

SARS-CoV-2-IN-109	SARS-CoV	Infection
SARS-CoV-2-IN-109 (compound 50) is an inhibitor targeting SARS-CoV with in vivo anti-infection activity. SARS-CoV-2-IN-109 targets the interaction between the SARS-CoV-2 Spike receptor-binding domain (RBD) and the human receptor angiotensin-converting enzyme 2 (ACE2) (EC₅₀=26.5 μM), blocking the entry of SARS-CoV-2 into VeroE6 cells (EC₅₀=17.0 μM). The CC50 of SARS-CoV-2-IN-109 for VeroE6 cells is >100 μM .

HY-P990815

Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) reacts with the receptor binding domain (RBD) epitope A in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can be used for the research of SARS-CoV-2 infection .

HY-P990814

Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) reacts with the receptor binding domain (RBD) epitope B in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can be used for the research of SARS-CoV-2 infection .

HY-15283AS1

(±)-Clopidogrel-d4 (±)-Clopidogrelum-d⁴	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
(±)-Clopidogrel-d₄ ((±)-Clopidogrelum-d₄) is the deuterium labeled (±)-Clopidogrel (HY-107867). (±)-Clopidogrel is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel has anti-inflammatory effects .

HY-P5407A

HD5 TFA	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection Cancer
HD5 TFA is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 TFA binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 TFA can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer .

Cat. No.	Product Name

HY-L145

Antihypertensive Compound Library	893 compounds
The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death. Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs). MCE offers a unique collection of 893 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Antihypertensive Compound Library

893 compounds

The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.

Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).

MCE offers a unique collection of 893 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Cat. No.	Product Name	Target	Research Area

HY-P1656

(D-Pro7)-Angiotensin I/II (1-7) 1 Publications Verification	Angiotensin Receptor Mas-related G-protein-coupled Receptor (MRGPR)	Cardiovascular Disease
(D-Pro7)-Angiotensin I/II (1-7) is a potent Mas receptor inhibitor with a K_i of 0.001 μM for rat receptors. (D-Pro7)-Angiotensin I/II (1-7) competitively blocks the binding of Angiotensin-(1-7) to the Mas receptor and attenuates the vasodilatory effect of rat aortas under physiological and hypertensive conditions. (D-Pro7)-Angiotensin I/II (1-7) can be used for studies on the function of the renin-angiotensin system and the pathological mechanisms of hypertension .

HY-P2141

TRV-120027 3 Publications Verification TRV027	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027, a β-arrestin-1-biased agonist of *the angiotensin* II receptor type 1 (AT1R)*, engages β-arrestins while blocking* G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R-β-arrestin-1-TRPC3-PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .

HY-P10933

PRO20	Renin	Cardiovascular Disease
PRO20 is a specific and competitive (pro)renin receptor (PRR) antagonist. PRO20 inhibits Prorenin-induced calcium influx with an IC₅₀ value of 81 nmol/L. PRO20 exerts antihypertensive activity by blocking the binding of prorenin to the PRR, inhibiting the activation of the renin-angiotensin system (RAS), and reducing the production of angiotensin II (Ang II). PRO20 is promising for research of antihypertensive agents .

HY-P5407

HD5	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection Cancer
HD5 is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer .

HY-P2141A

TRV-120027 TFA 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027 TFA, a β-arrestin-1-biased agonist of *the angiotensin* II receptor type 1 (AT1R)*, engages ?-arrestins while blocking* G-protein signaling . TRV120027?TFA induces?acute?catecholamine?secretion?through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the?acute decompensated heart failure (ADHF) treatment .

HY-P5407A

HD5 TFA	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection Cancer
HD5 TFA is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 TFA binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 TFA can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990951

Vixticibart REGN-5381	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease
Vixticibart (REGN-5381) is a fully human IgG4 monoclonal antibody and NPR1 agonist that targets NPR1. Vixticibart stabilizes the receptor in an activated conformation by binding to the N-terminal domain of NPR1, and enhances the activity of endogenous ligands ANP and BNP without blocking ligand binding when these ligands are present. Vixticibart exerts vasodilatory and hypotensive effects by inducing cGMP production, preferentially dilating venous vessels to reduce systolic and venous pressure, but does not induce diuresis and may trigger a compensatory increase in heart rate. Vixticibart produces a synergistic hypotensive effect when combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and is currently mainly used in research related to heart failure and hypertension .

HY-P990815

Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) reacts with the receptor binding domain (RBD) epitope A in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can be used for the research of SARS-CoV-2 infection .

HY-P990814

Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) reacts with the receptor binding domain (RBD) epitope B in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can be used for the research of SARS-CoV-2 infection .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N9530

1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone	Cardiovascular Disease Alkaloids Classification of Application Fields Evodia rutaecarpa (Juss.) Benth. Rutaceae Metabolic Disease Quinoline Alkaloids Plants Disease Research Fields Source Classification	Acyltransferase Angiotensin Receptor Bacterial
1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone, a quinolone alkaloid, is a diacylglycerol acyltransferase inhibitor and **angiotensin II receptor** blocker, with IC₅₀s of 20.1 μM and 34.1 μM, respectively. 1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone shows potent anti-Helicobacter pylori activity with the MIC of 10 μg/mL .

Cat. No.	Product Name	Chemical Structure

HY-12765S

Losartan-d4 (carboxylic acid)

Losartan-d₄ carboxylic acid (E-3174-d₄) is the deuterium labeled Losartan Carboxylic Acid (HY-12765). Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensin II receptor type 1 (AT1) antagonist. The K_i values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensin II-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure.

HY-B0205S

Candesartan-d4
Candesartan-d₄ (CV-11974-d₄) is the deuterium labeled Candesartan (HY-B0205). Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI).

HY-12765S1

Losartan carboxylic acid-d4 hydrochloride

Losartan carboxylic acid-d₄ (hydrochloride) is deuterium labeled Losartan Carboxylic Acid. Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensin II receptor type 1 (AT1) antagonist. The K_i values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensin II-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure .

HY-107867S1

(Rac)-Clopidogrel hydrogen-d9 sulfate

(Rac)-Clopidogrel hydrogen-d₉ sulfate is the deuterium labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-107867S2

Clopidogrel-13C,d3 sulfate

Clopidogrel- ¹³C,d₃ sulfate is the deuterium and ¹³C-labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-15283AS1

(±)-Clopidogrel-d4

(±)-Clopidogrel-d₄ ((±)-Clopidogrelum-d₄) is the deuterium labeled (±)-Clopidogrel (HY-107867). (±)-Clopidogrel is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel has anti-inflammatory effects .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

angiotensin receptor blockers

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products